ZA200604958B - LSA-5 liver stage and blood stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria - Google Patents

LSA-5 liver stage and blood stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria Download PDF

Info

Publication number
ZA200604958B
ZA200604958B ZA200604958A ZA200604958A ZA200604958B ZA 200604958 B ZA200604958 B ZA 200604958B ZA 200604958 A ZA200604958 A ZA 200604958A ZA 200604958 A ZA200604958 A ZA 200604958A ZA 200604958 B ZA200604958 B ZA 200604958B
Authority
ZA
South Africa
Prior art keywords
lsa
polypeptide
antibodies
antigen
peptides
Prior art date
Application number
ZA200604958A
Other languages
English (en)
Inventor
Druilhe Pierre
Brahimi-Zeghidour Karima
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of ZA200604958B publication Critical patent/ZA200604958B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA200604958A 2003-12-15 2004-12-15 LSA-5 liver stage and blood stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria ZA200604958B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03293158A EP1544211A1 (en) 2003-12-15 2003-12-15 LSA-5 pre-erythrocytic stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria

Publications (1)

Publication Number Publication Date
ZA200604958B true ZA200604958B (en) 2007-11-28

Family

ID=34486470

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200604958A ZA200604958B (en) 2003-12-15 2004-12-15 LSA-5 liver stage and blood stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria

Country Status (9)

Country Link
US (1) US8765145B2 (da)
EP (2) EP1544211A1 (da)
JP (1) JP4991308B2 (da)
CN (1) CN1922202A (da)
BR (1) BRPI0417286A (da)
CA (1) CA2548792C (da)
DK (1) DK1697405T3 (da)
WO (1) WO2005058948A1 (da)
ZA (1) ZA200604958B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100982064B1 (ko) * 2006-03-28 2010-09-13 원광대학교산학협력단 말라리아 원충에 대한 단일클론 항체 및 이를 이용한말라리아의 진단방법
CN101603964A (zh) * 2009-07-10 2009-12-16 中国海洋大学 海产品中异尖线虫的酶联免疫检测方法
CA3002946C (en) * 2009-11-05 2021-11-02 The United States Of America As Represented By The Secretary Of The Navy Plasmodium falciparum sporozoite and liver stage antigens
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
WO2016084944A1 (ja) * 2014-11-28 2016-06-02 国立大学法人 群馬大学 熱帯熱マラリア原虫のエノラーゼタンパク質の部分配列を用いた人工抗原とその製造方法
MX2018014253A (es) 2016-05-19 2019-11-11 Univ Pennsylvania Inmunógenos de malaria sintéticos, combinaciones de estos y su uso para prevenir y tratar infecciones de malaria.
CN113144222B (zh) * 2021-04-14 2023-05-23 台州学院 外泌体用于防止脑型疟疾发生的实验方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2566780B1 (fr) 1984-07-02 1987-02-06 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un epitope caracteristique d'une proteine produite par des cellules infectees par les parasites du paludisme et compositions les contenant
US20020076769A1 (en) * 2000-08-03 2002-06-20 Richard Brady Reduced molecular weight galactomannans oxidized by galactose oxidase
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens

Also Published As

Publication number Publication date
EP1697405B1 (en) 2012-09-05
JP2008504005A (ja) 2008-02-14
US8765145B2 (en) 2014-07-01
US20100183590A1 (en) 2010-07-22
CA2548792C (en) 2014-07-08
EP1544211A1 (en) 2005-06-22
BRPI0417286A (pt) 2007-04-10
WO2005058948A1 (en) 2005-06-30
EP1697405A1 (en) 2006-09-06
CN1922202A (zh) 2007-02-28
CA2548792A1 (en) 2005-06-30
DK1697405T3 (da) 2013-01-02
JP4991308B2 (ja) 2012-08-01

Similar Documents

Publication Publication Date Title
Singh et al. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design
Renia et al. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge
Fidock et al. Plasmodium falciparum sporozoite invasion is inhibited by naturally acquired or experimentally induced polyclonal antibodies to the STARP antigen
Lousada-Dietrich et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2–A GLURP–MSP3 fusion protein malaria vaccine candidate
Moreno et al. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice
Ling et al. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use
US20070003562A1 (en) GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it
CA2337754C (en) Recombinant multivalent malarial vaccine against plasmodium falciparum
EP1697405B1 (en) Lsa-5 liver stage and blood stage antigen of plasmodium falciparum, immunogenic composition comprising said antigen, and vaccines against malaria
US20020155441A1 (en) Polypeptide molecules of the pre-erythrocytic stage of malaria
US20110002916A1 (en) Plasmodium falciparum antigens and their vaccine and diagnostic applications
Chappel et al. Naturally acquired human antibodies which recognize the first epidermal growth factor-like module in the Plasmodium falciparum merozoite surface protein 1 do not inhibit parasite growth in vitro
US20180311326A1 (en) Immunoassemblin (ia) protein complexes
EP1526178B1 (en) MSP-3-like family of genes
Rogers et al. 15 Malaria Vaccines
US8188213B2 (en) Purified polypeptide comprising or consisting of a C-terminus MSP1 antigen from Plasmodium falciparum carrying a Glycosyl-phosphatidyl-inositol group (GPI)
Martin et al. Malaria vaccines in clinical development: Introduction and recombinant/subunit approaches
Amen Isolation and characterization of human monoclonal antibodies blocking Plasmodium falciparum transmission
Trager et al. Malaria vaccine
Stump Redesign and Evaluation of a Plasmodium falciparum Circumsporozoite Protein-based Malaria Vaccine
EP2223937A1 (en) Polypeptides for the prevention or treatment of malaria
Valero Monoclonal Antibodies Binding to Malarial Merozoite Surface Protein 1 Protect in vivo Against Plasmodium yoelii Infection
CHAPPEL et al. falciparum Merozoite Surface Protein Inhibit Parasite Growth In Vitro
Chai The humoral response to a chemically defined synthetic vaccine comprised of epitopes derived from the circumsporozoite protein of Plasmodium berghei
Chaun Vaccines for malaria--prospects and promise.